Klin Farmakol Farm. 2018;32(3):3-6 | DOI: 10.36290/far.2018.015

Determination of silybin content in food supplements containing silymarin

Martin Poruba, Zuzana Matušková
Ústav farmakologie, Lékařská fakulta Univerzity Palackého v Olomouci

The aim of this study was to determine the amount of silybin in selected nutraceuticals containing silymarin available in the CzechRepublic. The determination of silybin was performed using HPLC/UV. Results show that almost all of the tested nutraceuticalscontain the sufficient amount of silybin (range 20–40 %). NaturProdukt® Silymarin forte contained 40 % of silybin (80.00 ± 0.50 mg)and Nefdesanté® Silymarin ostropestřec contained 33 % of silybin (81.58 ± 0.14 mg). Both can be included among the products withhigh silybin content. On the other hand, the lowest amount of silybin was measured in WALMARK® Ostropestřec mariánský (< 20 %).Our results suggest that almost all of the tested products are of high quality and contain the declared amount of constituents.

Keywords: silymarin, silybin, nutraceuticals

Published: November 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Poruba M, Matušková Z. Determination of silybin content in food supplements containing silymarin. Klin Farmakol Farm. 2018;32(3):3-6. doi: 10.36290/far.2018.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytotherapy research: PTR. 2010; 24(10): 1423-1432. Go to original source... Go to PubMed...
    2. Rainone F. Milk thistle. American family physician. 2005; 72(7): 1285-1288. Go to PubMed...
    3. Skottova N, Vecera R, Urbanek K, Vana P, Walterova D, Cvak L. Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacological research. 2003; 47(1): 17-26. Go to original source... Go to PubMed...
    4. Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic A. Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of diabetes research. 2016; 2016: 5147468. Go to original source...
    5. Ferenci P, Beinhardt S. Silibinin: an old drug in the high tech era of liver transplantation. Journal of hepatology. 2013; 58(3): 409-411. Go to original source... Go to PubMed...
    6. Mihalčin M, Fašaneková L, ml., Husa P. Aktuální pohled na epidemiologii a přístupy k léčbě virových hepatitid A a E. Klinicka farmakologie a farmacie. 2017; 31(1): 15-18. Go to original source...
    7. Enjalbert F, Rapior S, Nouguier-Soule J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. Journal of toxicology Clinical toxicology. 2002; 40(6): 715-757. Go to original source... Go to PubMed...
    8. Hackett ES, Twedt DC, Gustafson DL. Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease. Journal of veterinary internal medicine. 2013; 27(1): 10-16. Go to original source... Go to PubMed...
    9. Lee JI, Narayan M, Barrett JS. Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2007; 845(1): 95-103. Go to original source...
    10. Bijak M. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism. Molecules (Basel, Switzerland). 2017; 22(11). Go to original source...
    11. Chambers CS, Holečková V, Petrásková L, Biedermann D, Valentová K, Buchta M, et al. The silymarin composition... and why does it matter??? Food Research International. 2017; 100: 339-353. Go to original source... Go to PubMed...
    12. Gunaratna C, Zhang T. Application of liquid chromatography-electrospray ionization-ion trap mass spectrometry to investigate the metabolism of silibinin in human liver microsomes. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2003; 794(2): 303-310. Go to original source...
    13. Radjabian T, Fallah Huseini H. Anti-hyperlipidemic and anti-atherosclerotic activities of silymarins from cultivated and wild plants of Silybum marianum L. with different content of flavonolignans. Iranian Journal of Pharmacology and Therapeutics. 2010; 9(2): 63-67.
    14. Poppe L, Petersen M. Variation in the flavonolignan composition of fruits from different Silybum marianum chemotypes and suspension cultures derived therefrom. Phytochemistry. 2016; 131: 68-75. Go to original source...
    15. Graf TN, Cech NB, Polyak SJ, Oberlies NH. A validated UHPLC-tandem mass spectrometry method for quantitative analysis of flavonolignans in milk thistle (Silybum marianum) extracts. Journal of pharmaceutical and biomedical analysis. 2016; 126: 26-33. Go to original source... Go to PubMed...
    16. Fathalah WF, Abdel Aziz MA, Abou El Soud NH, El Raziky MES. High Dose of Silymarin in Patients with Decompensated Liver Disease: A Randomized Controlled Trial. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2017; 37(11): 480-487. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.